Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring

Key Points

• Oura plans to debut on the Nasdaq under ticker OURA during the week of Sept. 28, offering 50 million shares priced between $40 and $44 for a valuation up to $15.6 billion fully diluted.
• Oura's subscription revenue grew 121% year over year to $240.5 million, helping lift gross margin to 55% and produce $60.8 million in net income for the nine months ended June 30, 2026.
• Eli Lilly indicated interest in buying up to $100 million of shares and partners with Oura on biometric tracking, reflecting growing pharmaceutical demand for the ring's health data platform.

Oura Inc. NASDAQ: OURA launched its roadshow on Sept. 21, 2026, targeting a Nasdaq debut under the ticker OURA during the week of Sept. 28. Offering 50 million shares priced between $40 and $44 each, Oura is targeting an initial market capitalization of around $12.8 billion to $14.1 billion, representing approximately $15.6 billion on a fully diluted basis.

Hardware debuts frequently face investor skepticism over cyclical consumer tastes, yet this transaction presents an evolving financial profile. Backed by direct institutional interest from major pharmaceutical leaders, Oura is transforming from a personal wellness device into an essential biometric data layer for metabolic healthcare. Understanding how those fundamentals interact helps clarify where value lies as trading begins.

Oura’s IPO Tests a Premium Valuation

Hardware makers often struggle with uneven revenue because sales depend on multi-year upgrade cycles. When a customer buys a physical device once every three or four years, total customer lifetime value stays limited. Oura tackles this structural hurdle by pairing titanium rings with an ongoing membership model priced at $5.99 per month.

Regulatory filings reveal how rapidly this recurring model is expanding. For the nine months ended June 30, 2026, membership software revenue grew about 121% year over year (YOY) to around $240.5 million. Total net revenue advanced about 74% YOY to $1.21 billion during the same period, showing that predictable subscription cash flows are compounding at nearly double the pace of physical ring shipments.

Oura's engagement metrics explain that operational velocity. Oura supports around five million active paid members across 56 geographic markets. These users record a median daily wear time of 23 hours, generating an active ratio of roughly 65% for daily active users compared to monthly active users. The platform also preserves an 85% 12-month paid subscriber retention rate.

In fundamental economics, high user engagement paired with durable retention lowers long-term customer acquisition costs. That operating leverage pushed gross margin up to 55% from 51% in the prior-year period. It also propelled Oura into positive operational profitability, producing $60.8 million in net income and around $106.7 million in earnings before interest, taxes, depreciation, and amortization (EBITDA).

Big Pharma Is Buying Into the Ring

The defining fundamental catalyst behind recent institutional demand is the intersection of consumer wearables and clinical metabolic therapy. As millions of patients begin glucagon-like peptide-1 (GLP-1) treatments for diabetes and weight management, medical practitioners face a practical hurdle: observing continuous physiological responses outside clinic visits.

Oura entered this workflow by introducing software features that track heart rate variability, sleep quality shifts, and lean muscle retention during weight-loss regimens. That clinical functionality attracted pharmaceutical leader Eli Lilly and Company NYSE: LLY, which indicated interest in buying up to $100 million of common stock in the offering. Eli Lilly already collaborates with Oura to integrate biometric tracking through the LillyDirect digital healthcare channel, offering patients and doctors continuous data on treatment response.

Expanding that health infrastructure, an operational partnership with continuous biosensor pioneer Dexcom Inc. NASDAQ: DXCM connects glucose readings from the Stelo sensor directly into the Oura mobile software.

This integration creates a two-way feedback loop, enabling members to see how nutritional spikes affect overnight resting heart rates and daytime recovery scores. By establishing these clinical connections, Oura transitions from a consumer fitness gadget into a continuous monitoring asset.

How Oura Stacks Up Against Wearable Peers

Evaluating Oura requires balancing hardware production realities against high-margin software multiples. At the midpoint price of $42 per share, Oura trades at around 9.7x annualized sales, based on its latest nine-month run rate.

Traditional consumer electronics manufacturers like Garmin Ltd. NYSE: GRMN trade closer to 7.5x sales, while diversified technology leaders like Apple Inc. NASDAQ: AAPL command roughly 12x sales.

Institutional backers, including Dragoneer Investment Group with an indicated order of up to $300 million, appear comfortable paying a growth premium because Oura is generating 74% top-line revenue growth while delivering positive net income. Most initial public offerings over recent years entered public markets with widening operational deficits.

Proprietary intellectual property also provides a defensive barrier around this multiple. Following patent enforcement proceedings before the U.S. International Trade Commission, Oura secured licensing agreements and recurring royalties from competing smart ring brands. Those legal protections limit low-cost overseas manufacturers from copying its miniaturized sensor package without paying royalties.

Patent Strength Comes With Legal Risk

Investors should weigh these fundamental advantages against distinct operational risks. Ring hardware sales still generate approximately 80% of total revenue. Despite rapid subscription gains, Oura remains exposed to cyclical swings in discretionary consumer spending and component supply chain disruptions.

Capital allocation details in the registration filing also deserve a close look. Of the 50 million shares offered, existing stockholders are selling 36.5 million, providing venture backers with significant early liquidity. Out of the estimated $532.6 million in net primary proceeds raised at the midpoint, roughly $526.4 million is designated to cover tax withholding and remittance obligations tied to restricted stock unit settlements. That allocation leaves limited primary capital to fund external acquisitions or build cash reserves.

Investors should also track an active consumer class-action lawsuit disclosed in the regulatory paperwork. The litigation challenges the scientific precision and advertising claims about the accuracy of Oura's sleep-tracking technology. While patent strength remains solid, an unfavorable outcome in the case could create reputational headwinds or require adjustments to product marketing claims.

What to Watch as Oura Begins Trading

Oura's Nasdaq debut introduces a pure-play health intelligence business that integrates daily consumer habits with pharmaceutical adherence. With retail access available through brokerages like Robinhood Markets Inc. NASDAQ: HOOD, opening volume could see active retail participation alongside institutional anchors.

Investors reviewing the debut can monitor how final pricing settles within the $40 to $44 range and watch early price stability as underwriting syndicates balance supply. Cautious investors may prefer to wait for post-listing volatility to subside before establishing an equity position. Long-term investors can use upcoming quarterly earnings reports to confirm whether subscription momentum remains above 120% and gross margin remains near 55% as public market life begins.